# Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine

> **NIH NIH N43** · ADJUVANCE TECHNOLOGIES, INC. · 2020 · $44,297

## Abstract

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenic, requiring use of an immunological adjuvant for best effect. Adjuvance's semi-synthetic saponin adjuvant TiterQuil-1055 (TQL1055) has demonstrated efficacy with a variety of antigens with no detectable reactogenicity. The objectives of the Phase I project are to test whether TQL1055 can enhance the immunogenicity and efficacy of influenza vaccines, and to conduct IND enabling stability studies.

## Key facts

- **NIH application ID:** 10164671
- **Project number:** 75N93019C00016-P00002-9999-1
- **Recipient organization:** ADJUVANCE TECHNOLOGIES, INC.
- **Principal Investigator:** TYLER MARTIN
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $44,297
- **Award type:** —
- **Project period:** 2019-06-16 → 2020-12-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10164671

## Citation

> US National Institutes of Health, RePORTER application 10164671, Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine (75N93019C00016-P00002-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10164671. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*